

PRESS RELEASE

## **Sunstone appoints Jacob Lange Moresco as Investment Director**

**Copenhagen, 7 February 2019** – After a successful first closing of Sunstone Life Science Ventures Fund IV, Sunstone today announced the appointment of Jacob Lange Moresco, PhD, as Investment Director. Jacob will be joining Sunstone on 1 March 2019 and will be part of the team investing from the new fund. The investment strategy of the new fund is a continuation of Sunstone’s successful strategy of investing in novel therapeutics with the potential to improve the quality of patient care and treatment. The typical investments are based on strong science and technology with innovative products addressing unmet medical needs within the framework of an attractive business case.

Jacob is coming from a position as Senior Manager, Global Business Development, at LEO Pharma, where he has been actively pursuing strategic partnerships and M&A opportunities, and performing strategic R&D pipeline analyses. Most recently, Jacob worked on the transaction in which LEO Pharma acquired certain rights and a minority equity stake in PellePharm, Inc. with the aim to advance innovative therapies for rare skin diseases. Before that Jacob had a 4-year tenure as Associate at Sunstone Life Science Ventures.

Commenting on the announcement, Søren Lemonius, Managing General Partner, said: “We are very pleased that Jacob has decided to re-join the Sunstone investment team - now with several years of relevant industry experience and an extensive network. With the combined experience and track record of the team we are well positioned to execute on the strategy that will bring novel and effective therapies to patients in need.”

"I'm excited to join the Sunstone team and look forward to working with early stage biotech at the forefront of therapeutic innovation and for the benefit of patients worldwide" said Jacob Lange Moresco.

### **About Sunstone:**

Sunstone Life Science Ventures is an independent European venture capital investment firm founded in 2007 by an international team of industry experts with combined entrepreneurial, operational and financial experience. Sunstone Life Science Ventures focuses on developing and expanding early-stage Life Science companies with strong potential to achieve global success in their markets. Since the inception, Sunstone Life Science Ventures has invested in more than 40 companies in the areas of pharmaceuticals, medical technologies and diagnostics, and has completed more than 20 successful IPOs and large M&A transactions. Managing total funds of approx. €500 million, Sunstone Life Science Ventures is one of the largest European venture capital investors.

### **Sunstone contacts:**

Søren Lemonius  
Managing General Partner  
+45 40 81 48 89  
[lemonius@sunstone.eu](mailto:lemonius@sunstone.eu)

Sunstone Life Science Ventures A/S - Lautrupsgade 7, 5 - DK-2100 Copenhagen, Denmark  
<http://life.sunstone.eu>